Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04519905
NA

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

Sponsor: Fudan University

View on ClinicalTrials.gov

Summary

So far, there is no specific clinical guideline for elderly patients (\>75 yr) with esophageal squamous cell carcinoma (ESCC). Patients with locally advanced ESCC were enrolled and randomly assigned to either definitive radiotherapy group (61.2Gy/34Fx) or the chemoradiotherapy group (50.4Gy/28Fx;Paclitaxel plus carboplatin). The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival.

Key Details

Gender

All

Age Range

76 Years - Any

Study Type

INTERVENTIONAL

Enrollment

320

Start Date

2020-01-06

Completion Date

2027-12

Last Updated

2021-11-02

Healthy Volunteers

No

Interventions

DRUG

Paclitaxel plus carboplatin

Paclitaxel (45mg/m2) plus carboplatin (AUC=2); five cycles; qw

RADIATION

radiotherapy

Different radiotherapy dose in different groups.

Locations (3)

Jiangsu Cancer Hospital

Nanjing, Jiangsu, China

Huadong Hospital

Shanghai, Shanghai Municipality, China

Fudan Universtiy Shanghai Cancer Center

Shanghai, Shanghai Municipality, China